Prospective, doubleblind, randomized, placebocontrolled Trial with Abciximab to reduce coronary microembolism during PCI in patient with stable angina pectoris.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 28 May 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abciximab (Primary)
Indications Embolism
Focus Biomarker; Therapeutic Use
Acronyms REOPRO-HITS

Most Recent Events

09 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2010-019688-12).
09 Feb 2013 Planned End Date (18 Apr 2011) added as reported by European Clinical Trials Database.
06 Jul 2012 Planned initiation date (12 Dec 2010) added as reported by German Clinical Trials Register record..

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight